Metformin: A Unique Herbal Origin Medication

Farah Yousef
Farah Yousef * §
Contact
Nadin Yousef
Nadin Yousef §
Contact
§ Damascus University Damascus University

Send Message

To: Author

Metformin: A Unique Herbal Origin Medication

Article Fingerprint

ReserarchID

PDDTMKDS2I

Metformin: A Unique Herbal Origin Medication Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
Access Review Comments
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background
This converted HTML version may contain rendering inconsistencies. Please refer to the PDF for the authoritative version, or click here to provide feedback.

Abstract

Many oral anti-hyperglycemic agents have been used for treatment of Type II diabetes (TY2D), yet Metformin, the only compound remained of biguanide derivates, continued to be used in this treatment. Its mechanism of action and pharmacokinetics are unique and significant. It has low side effects and no adverse incidences with healthy heart and kidney T2D, compared with its family group members. The previous properties made metformin tops the oral anti hyperglycemic agents list recommended from FDA in TY2D therapy. In this review paper, we aimed to point at bi-guanide development through time as glucose lowering agents, and show the magnificent characteristics of dimethylbiguanide; metformin.

References

83 Cites in Article
  1. 1. (1985). Guanidines. Guanidineshistorical, biological, biochemical and clinical aspects of the naturally occurring guanidine compounds
  2. 2. Clifford Bailey,Caroline Day (1989). Traditional Plant Medicines as Treatments for Diabetes. Diabetes Care, 12(8), 553-564.
  3. 3. Clifford Bailey (1992). Biguanides and NIDDM. Diabetes Care, 15(6), 755-772.
  4. 4. H Leclerc,Le Galega (1928). Unknown Title. Presse Med
  5. 5. J Duke (2002). Handbook of medicinal herbs. Handbook of medicinal herbs, 337.
  6. 6. H Muller,H Rheinwein (1927). Pharmacology of galegin. Arch Exp Path Pharmacol, 125, 212-228.
  7. 7. F Bischoff,M Sahyun,M Long (2017). Guanidine Structure and Hypoglycemia. Guanidine Structure and Hypoglycemia
  8. 8. G Ungar,L Freedman,S Shapiro (1957). Pharmacological Studies of a New Oral Hypoglycemic Drug. Experimental Biology and Medicine, 95(1), 190-192.
  9. 9. H Mehnert,W Seitz (1958). Weitere Ergebnisse der diabetesbehandlung mit blutzuckersenkenden biguaniden. Munch Med Wschr, 100, 1849-1851.
  10. 10. Jorge Mestman,M Dean,S Pocock,M,Arthur Kirchner,M Los,Angeles (1969). Lactic Acidosis with Recovery In Diabetes Mellitus On Phenformin Therapy. Califrina Medicine, 3
  11. 11. C William,Gong,B Donald,Kato Phenformin Induced Lactic Acidosis. Drag Intelligence and Clinical Pharmacy, 9, 236-240.
  12. 12. M Nattrass,K Alberti,Biguanides (1978). Unknown Title. Diabetologia, 14, 71-74.
  13. 13. J Sterne (1969). Oral Hypoglycaemic Agents. Encyclopedia of Molecular Pharmacology, 907-907.
  14. 14. L Hermann (1979). Metformin: a review of history, pharmacodynamics and therapy. Diabetes Metab Rev, 5, 233-245.
  15. 15. Clifford Bailey,Robert Turner (1996). Metformin. New England Journal of Medicine, 334(9), 574-579.
  16. 16. Meiter Ch,Bodmer M (2008). Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes care, 31, 2086-2091.
  17. 17. American Diabetes,Association (2002). Implication of the united kingdome prospective diabetes study. Diabetes Care, 25, 52832.
  18. 18. El-Bayouki Kh,R Abdel-Rahman (2016). Synthesis and evaluation of 1-substituted-biguanide derivates as anti-diabetic agents for type II diabetes Insulin Resistant. Drug Res, 66, 1-7.
  19. 19. Seymour Shapiro,Vincent Parrino,Elaine Rogow,Louis Freedman (1959). Hypoglycemic Agents. II.1—3 Arylbiguanides. Journal of the American Chemical Society, 81(14), 3725-3728.
  20. 20. A Shalmalshi (2008). New Route to Metformin Hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) Synthesis. Molbank, 2008(1), M564.
  21. 21. John Scarpello,Harry Howlett (2008). Metformin therapy and clinical uses. Diabetes and Vascular Disease Research, 5(3), 157-167.
  22. 22. S Inzucchi,R Bergenstal,J Buse,M Diamant,E Ferrannini,M Nauck (2012). Management of hyperglycemia in type 2 diabetes: A patient centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 136479.
  23. 23. Nicolas Michael,F Hirshman (2002). Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects with Type 2. Diabetes, 51, 2074-2081.
  24. 24. Mengwei Zang,Adriana Zuccollo,Xiuyun Hou,Daisuke Nagata,Kenneth Walsh,Haya Herscovitz,Peter Brecher,Neil Ruderman,Richard Cohen (2004). AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells. Journal of Biological Chemistry, 279(46), 47898-47905.
  25. 25. Mohamad-Yehia El-Mir,Véronique Nogueira,Eric Fontaine,Nicole Avéret,Michel Rigoulet,Xavier Leverve (2000). Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I. Journal of Biological Chemistry, 275(1), 223-228.
  26. 26. Arian Emami Riedmaier,Pascale Fisel,Anne Nies,Elke Schaeffeler,Matthias Schwab (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends in Pharmacological Sciences, 34(2), 126-135.
  27. 27. X Leverve,B Guigas,D Detaille,C Batandier,E Koceir,C Chauvin (2003). Mitochondrial metabolism and type2 diabetes: A specific target of metformin. Diabetes Metab, 29, 6S-8894.
  28. 28. A Halestrap,Owen M (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical society, 607-614.
  29. 29. X Leverve,B Guigas,D Detaille,C Batandier,E Koceir,C Chauvin,E Fontaine,N Wiernsperger (2003). Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes & Metabolism, 29(4), 6S88-6S94.
  30. 30. R Miller,Q Chu,J Xie,M Foretz,B Viollet,M Birnbaum (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature, 494, 25660.
  31. 31. Benoit Viollet,Bruno Guigas,Nieves Garcia,Jocelyne Leclerc,Marc Foretz,Fabrizio Andreelli (2012). Cellular and molecular mechanisms of metformin: an overview. Clinical Science, 122(6), 253-270.
  32. 32. Paul Caton,Nanda Nayuni,Julius Kieswich,Noorafza Khan,Muhammed Yaqoob,Roger Corder (2010). Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. Journal of Endocrinology, 205(1), 97-106.
  33. 33. Ling He,Amin Sabet,Stephen Djedjos,Ryan Miller,Xiaojian Sun,Mehboob Hussain,Sally Radovick,Fredric Wondisford (2009). Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding Protein. Cell, 137(4), 635-646.
  34. 34. M Foretz,S Hébrard,J Leclerc,E Zarrinpashneh,M Soty,G Mithieux (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest, 120, 235569.
  35. 35. A Scheen (1996). Clinical pharmacokinetics of metformin. Clin Pharmacokinet, 30, 359-371.
  36. 36. J Arora,M Day,R Doogue,M Duong,J (2011). Clinical pharmacokinetics of metformin. Clin Pharmacokinet, 50, 81-98.
  37. 37. (2011). Summary of Revisions to the 2011 Clinical Practice Recommendations. Diabetes Care, 34(Supplement_1), S3-S3.
  38. 38. Robert Turner,C Cull,V Frighi,R Holman (1999). Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49). JAMA, 281(21), 2005.
  39. 39. Harry Howlett,Clifford Bailey (1999). A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus. Drug Safety, 20(6), 489-503.
  40. 40. S Inzucchi,R Bergenstal,J Buse,M Diamant,E Ferrannini,M Nauck (2012). Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 55, 1577-1596.
  41. 41. W Bennett,N Maruthur,S Singh,J Segal,L Wilson,R Chatterjee (2011). Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2drug combinations. Ann Intern Med, 154, 602-613.
  42. 42. P Raskin (2008). Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 10(12), 1167-1177.
  43. 43. Bernard Charbonnel,Avraham Karasik,Ji Liu,Mei Wu,Gary Meininger (2006). Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone. Diabetes Care, 29(12), 2638-2643.
  44. 44. John Gerich,Philip Raskin,Lisa Jean-Louis,Das Purkayastha,Michelle Baron (2005). PRESERVE-β. Diabetes Care, 28(9), 2093-2099.
  45. 45. M González-Ortiza,J Guerrero-Romero,Violante Ortiz,R (2009). Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications, 23, 376-379.
  46. 46. L Tock,A Dˆamaso,A De Piano,J Carnier (2010). Long-Term Effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents. J Obes, 6.
  47. 47. Min Park,Sanjay Kinra,Kirsten Ward,Billy White,Russell Viner (2009). Metformin for Obesity in Children and Adolescents: A Systematic Review. Diabetes Care, 32(9), 1743-1745.
  48. 48. Lawrence Blonde,George Dailey,Serge Jabbour,Charles Reasner,Donna Mills (2004). Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion, 20(4), 565-572.
  49. 49. Juliana Levy,Roberta Cobas,Marília Gomes (2010). Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 2(1), 16.
  50. 50. I Raz,I Delaet,H Goyvaerts (2000). Safety and efficacy of novel extended release formulation of metformin in patients with type 2 diabetes. Diabetes, 49(Suppl 1), 363.
  51. 51. Jeffrey Johnson,Sumit Majumdar,Scot Simpson,Ellen Toth (2002). Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes. Diabetes Care, 25(12), 2244-2248.
  52. 52. A; Scheen,N Paquot (2013). Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes. Diabetes & Metabolism, 39(3), 179-190.
  53. 53. D Hulisz,M Bonfiglio,R Murray (1998). Metformin-Associated Lactic Acidosis. The Journal of the American Board of Family Medicine, 11(3), 233-236.
  54. 54. Diabetes Uk Prospective,( Study,Ukpds) Group (1998). Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
  55. 55. (1998). UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
  56. 56. D Giugliano,A Quatraro,G Consoli,A Minei,A Ceriello,N De Rosa,F D'onofrio (1993). Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. European Journal of Clinical Pharmacology, 44(2), 107-112.
  57. 57. S Vella,L Buetow,P Royle,S Livingstone,H Colhoun,J Petrie (2010). The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia, 53(5), 809-820.
  58. 58. S Abdelghaffar,A Attia (2009). Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev, 6691.
  59. 59. S Wiegand,U Maikowski,O Blankenstein,H Bierbermann,P Tarnow,A Grutes (2004). Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity-a problem that is no longer restrited to minority groups. Eur J Endocrinol, 151, 199-206.
  60. 60. Orit Pinhas-Hamiel,Phil Zeitler (2007). Clinical presentation and treatment of type 2 diabetes in children. Pediatric Diabetes, 8(s9), 16-27.
  61. 61. Kenneth Jones,Silva Arslanian,Valentina Peterokova,Jong-Soon Park,Mark Tomlinson (2002). Effect of Metformin in Pediatric Patients With Type 2 Diabetes. Diabetes Care, 25(1), 89-94.
  62. 62. Stefano Palomba,Angela Falbo,Fulvio Zullo,Francesco Orio (2009). Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review. Endocrine Reviews, 30(1), 1-50.
  63. 63. M Balasubramanyam (2014). Metformin: Nature′s gift that keeps on giving more!. Journal of Obesity and Metabolic Research, 1(2), 118.
  64. 64. Vladimir Anisimov (2013). Metformin: Do we finally have an anti-aging drug?. Cell Cycle, 12(22), 3483-3489.
  65. 65. M Yin,J Zhou,E Gorak,F Quddus (2013). Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and metaanalysis. Oncologist, 18, 124855.
  66. 66. Diana Hatoum,Eileen Mcgowan (2015). Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?. BioMed Research International, 2015, 1-13.
  67. 67. Mihaela Aldea,Lucian Craciun,Ciprian Tomuleasa,Ioana Berindan-Neagoe,Gabriel Kacso,Ioan Florian,Carmen Crivii (2014). Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery. Tumor Biology, 35(6), 5101-5110.
  68. 68. M Krempf,K Parhofer,G Steg (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation, 106(25), 3143-3143.
  69. 69. Adriaan Kooy,Jolien De Jager,Philippe Lehert,Daniël Bets,Michiel Wulffelé,Ab Donker,Coen Stehouwer (2009). Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus. Archives of Internal Medicine, 169(6), 616.
  70. 70. C Vitale,G Mercuro,A Cornoldi,M Fini (2005). Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med, 258, 250-256.
  71. 71. Miloš Spasić,Patrick Callaerts,Koenraad Norga (2009). AMP-Activated Protein Kinase (AMPK) Molecular Crossroad for Metabolic Control and Survival of Neurons. The Neuroscientist, 15(4), 309-316.
  72. 72. Lars Van Der Heide,Geert Ramakers,Marten Smidt (2006). Insulin signaling in the central nervous system: Learning to survive. Progress in Neurobiology, 79(4), 205-221.
  73. 73. Thomas Sulkin,Deborah Bosman,Andrew Krentz (1997). Contraindications to Metformin Therapy in Patients With NIDDM. Diabetes Care, 20(6), 925-928.
  74. 74. J Evans,S Ogston,A Emslie-Smith,A Morris (2006). Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia, 49, 930-936.
  75. 75. Peter Lurie,Joshua Sharfstein (2006). Product Approval and Public Health at the US Food and Drug Administration. JAMA, 326(24), 2469.
  76. 76. Amy Calabrese,Kim Coley,Stacey Dapos,Dennis Swanson,R Rao (2002). Evaluation of Prescribing Practices. Archives of Internal Medicine, 162(4), 434.
  77. 77. Kasia Lipska,Clifford Bailey,Silvio Inzucchi (2011). Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care, 34(6), 1431-1437.
  78. 78. A Frid,G Sterner,M Londahl (2010). Novel assay of metformin levels in patients with type 2 diabetes mellitus and varying levels of renal function. Diabetes Care, 33, 1291-1293.
  79. 79. J Jager,A Kooy,P Lehert,M Wulffelé (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled trial. BMJ, 340, 2181.
  80. 80. Wei Ting,R Szeto,C Chan,M Ma,K (2006). Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Arch Intern Med, 166, 1975-1979.
  81. 81. Lilian Rojas,Marilia Gomes (2013). Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome, 5(1), 6.
  82. 82. (2003). Glucophage. Drugs Handbook 2012–2013
  83. 83. Leland Gershell (2005). Type 2 diabetes market. Nature Reviews Drug Discovery, 4(5), 367-368.
Show All References
Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Farah Yousef, Nadin Yousef. 2017. "Metformin: A Unique Herbal Origin Medication". Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 17 (GJMR Volume 17 Issue B3).

More Citation Formats

Download Citation

  • Open Access
  • CC-BY-ND-NC 4.0
Download Article
Access OJS
Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Not Found
Classification
GJMR-B Classification NLMC Code: QV 767
  • Submission ReceivedDecember 11, 2016
  • Peer Review Double Blind
    Handling Editor
  • Accepted January 4, 2017
  • Published January 15, 2017
Version of record

v1.2

Issue date
November 3, 2017

Language
English
Order Article Reprint
Experience in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 1.5K
Total Downloads: 91
All Trends

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Metformin: A Unique Herbal Origin Medication

Farah Yousef
Farah Yousef Damascus University
Nadin Yousef
Nadin Yousef <p>Damascus University</p>
  • Submission ReceivedDecember 11, 2016
  • Peer Review Double Blind
    Handling Editor
  • Accepted January 4, 2017
  • Published January 15, 2017